Mucosal immunity and novel tuberculosis vaccine strategies: Route of immunisationdetermined T-cell homing to restricted lung mucosal compartments

European Respiratory Review

Volumn 24, Issue 136, 2015, Pages 356-360

  Lai, Rocky ^a   Afkhami, Sam ^a   Haddadi, Siamak ^a   Jeyanathan, Mangalakumari ^a   Xing, Zhou ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADHU5AG85A VACCINE; BCG VACCINE; MVAAG85A VACCINE; UNCLASSIFIED DRUG; AUTACOID;

ARTICLE; CELLULAR DISTRIBUTION; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INNATE IMMUNITY; LUNG BLOOD VESSEL; LUNG INTERSTITIUM; LUNG TUBERCULOSIS; LYMPHOCYTE HOMING; MUCOSAL IMMUNITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; RESPIRATORY TRACT MUCOSA; T LYMPHOCYTE; ANIMAL; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; LUNG; MICROBIOLOGY; NEUTROPHIL CHEMOTAXIS; PATHOGENICITY; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

ADMINISTRATION, INHALATION; ANIMALS; CHEMOTAXIS, LEUKOCYTE; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION; INFLAMMATION MEDIATORS; LUNG; MYCOBACTERIUM TUBERCULOSIS; T-LYMPHOCYTES; TREATMENT OUTCOME; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY;

EID: 84930462885     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.00002515     Document Type: Article

References (35)

1. 1 World Health Organization. Global Tuberculosis Report 2014. Geneva, WHO Press, 2014.
2. 2 Shaler CR, Horvath C, Lai R, et al. Understanding delayed T-cell priming, lung recruitment, and airway luminal T-cell responses in host defense against pulmonary tuberculosis. Clin Dev Immunol 2012; 2012: 628293.
3. 3 Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009; 27: 393–422.
4. 4 Davenport MP, Belz GT, Ribeiro RM. The race between infection and immunity: How do pathogens set the pace? Trends Immunol 2009; 30: 61–66.
5. 5 Horvath CN, Shaler CR, Jeyanathan M, et al. Mechanisms of delayed anti-tuberculosis protection in the lung of parenteral BCG-vaccinated hosts: A critical role of airway luminal T cells. Mucosal Immunol 2012; 5: 420–431.
6. 6 Xing Z, Jeyanathan M, Smaill F. New approaches to TB vaccination. Chest 2014; 146: 804–812.
7. 7 Xing Z, Lichty BD. Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis (Edinb) 2006; 86: 211–217.
8. Smaill F, Jeyanathan M, Smieja M, et al. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med 2013; 5: 205ra134.
9. 9 Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial. Lancet 2013; 381: 1021–1028.
10. 10 Lai R, Jeyanathan M, Shaler CR, et al. Restoration of innate immune activation accelerates Th1-cell priming and protection following pulmonary mycobacterial infection. Eur J Immunol 2014; 44: 1375–1386.
11. 11 Jeyanathan M, Heriazon A, Xing Z. Airway luminal T cells: A newcomer on the stage of TB vaccination strategies. Trends Immunol 2010; 31: 247–252.
12. 12 Wang J, Thorson L, Stokes RW, et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 2004; 173: 6357–6365.
13. 13 Santosuosso M, Zhang X, McCormick S, et al. Mechanisms of mucosal and parenteral tuberculosis vaccinations: Adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen. J Immunol 2005; 174: 7986–7994.
14. 14 Santosuosso M, McCormick S, Roediger E, et al. Mucosal luminal manipulation of T cell geography switches on protective efficacy by otherwise ineffective parenteral genetic immunization. J Immunol 2007; 178: 2387–2395.
15. 15 Tschernig T, Pabst R. What is the clinical relevance of different lung compartments? BMC Pulm Med 2009; 9: 39.
16. 16 Anderson KG, Sung H, Skon CN, et al. Cutting edge: Intravascular staining redefines lung CD8 T cell responses. J Immunol 2012; 189: 2702–2706.
17. 17 Sakai S, Kauffman KD, Schenkel JM, et al. Cutting edge: control of Mycobacterium tuberculosis infection by a subset of lung parenchyma-homing CD4 T cells. J Immunol 2014; 192: 2965–2969.
18. 18 Mackay LK, Rahimpour A, Ma JZ, et al. The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin. Nat Immunol 2013; 14: 1294–1301.
19. 19 Annacker O, Coombes JL, Malmstrom V, et al. Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J Exp Med 2005; 202: 1051–1061.
20. 20 Wakim LM, Gupta N, Mintern JD, et al. Enhanced survival of lung tissue-resident memory CD8+ T cells during infection with influenza virus due to selective expression of IFITM3. Nat Immunol 2013; 14: 238–245.
21. Baaten BJ, Cooper AM, Swain SL, et al. Location, location, location: the impact of migratory heterogeneity on T cell function. Front Immunol 2013; 4: 311.
22. Iwata M, Hirakiyama A, Eshima Y, et al. Retinoic acid imprints gut-homing specificity on T cells. Immunity 2004; 21: 527–538.
23. 23 McCully ML, Ladell K, Hakobyan S, et al. Epidermis instructs skin homing receptor expression in human T cells. Blood 2012; 120: 4591–4598.
24. 24 McCully ML, Moser B. The human cutaneous chemokine system. Front Immunol 2011; 2: 33.
25. 25 Mora JR, Bono MR, Manjunath N, et al. Selective imprinting of gut-homing T cells by Peyer’s patch dendritic cells. Nature 2003; 424: 88–93.
26. 26 Mikhak Z, Strassner JP, Luster AD. Lung dendritic cells imprint T cell lung homing and promote lung immunity through the chemokine receptor CCR4. J Exp Med 2013; 210: 1855–1869.
27. 27 Ferguson AR, Engelhard VH. CD8 T cells activated in distinct lymphoid organs differentially express adhesion proteins and coexpress multiple chemokine receptors. J Immunol 2010; 184: 4079–4086.
28. 28 Lee LN, Ronan EO, de Lara C, et al. CXCR6 is a marker for protective antigen-specific cells in the lungs after intranasal immunization against Mycobacterium tuberculosis. Infect Immun 2011; 79: 3328–3337.
29. 29 Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol Ther 2004; 10: 616–629.
30. 30 Muruve DA. The innate immune response to adenovirus vectors. Hum Gene Ther 2004; 15: 1157–1166.
31. 31 Jeyanathan M, Damjanovic D, Shaler CR, et al. Differentially imprinted innate immunity by mucosal boost vaccination determines antituberculosis immune protective outcomes, independent of T-cell immunity. Mucosal Immunol 2013; 6: 612–625.
32. 32 Ambrose CS, Wu X, Knuf M, et al. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: A meta-analysis of 8 randomized controlled studies. Vaccine 2012; 30: 886–892.
33. 33 Dilraj A, Cutts FT, de Castro JF, et al. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: A randomised trial. Lancet 2000; 355: 798–803.
34. 34 Dilraj A, Sukhoo R, Cutts FT, et al. Aerosol and subcutaneous measles vaccine: Measles antibody responses 6 years after re-vaccination. Vaccine 2007; 25: 4170–4174.
35. 35 Satti I, Meyer J, Harris SA, et al. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial. Lancet Infect Dis 2014; 14: 939–946.